TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07637578: A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Sponsor: SCRI Development Innovations, LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 46 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,524,600

Rescue Site Savings

+$1,016,400

Unlock Full NCT07637578 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07637578 Rescue Dossier →